Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A   Lamos Elizabeth M   Davis Stephen N  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite

Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors

By Masuda Kiyomi   Aoki Kazutaka   Kamiko Kazunari   Takihata Masahiro   Ito Yuzuru   Nagakura Mieko   Kawasaki Satsuki   Akema Noriko   Hasegawa Maki   Nakajima Shigeru   Shinoda Kazuaki   Toumura Shyoken   Tsunoda Seishi   Enomoto Hitoshi   Shimotomai Hidefumi   Terauchi Yasuo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1111-1118

Informa Healthcare

Access to resources Recommend Favorite

Discovery of JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes.

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 557-568

Bentham Science Publishers

Access to resources Recommend Favorite

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

By Fujii Yuki   Abe Masanori   Higuchi Terumi   Mizuno Mari   Suzuki Hiroko   Matsumoto Shiro   Ito Midori   Maruyama Noriaki   Okada Kazuyoshi   Soma Masayoshi  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 3, 2013-02 ,pp. : 259-267

Informa Healthcare

Access to resources Recommend Favorite

Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment

By  

Current Drug Targets, Vol. 15, Iss. 6, 2014-06 ,pp. : 600-621

Bentham Science Publishers

Access to resources Recommend Favorite